Breaking News Instant updates and real-time market news.

AAPL

Apple

$113.89

0.84 (0.74%)

, GOOG

Alphabet

$776.86

0.39 (0.05%)

16:31
10/06/16
10/06
16:31
10/06/16
16:31

On The Fly: Top stock stories for Thursday

Stocks began the session with moderate losses and the averages moved in a narrow range until a report surfaced that the ECB would continue its quantitative easing program until it was on a path to hitting its inflation targets. The news turned the market and brought the averages to essentially even, but it was not enough to gain any positive momentum. Investors appear to be on the sidelines waiting for tomorrow's jobs data and bracing themselves for the potential damage from Hurricane Matthew, which is scheduled to make landfall later this evening. ECONOMIC NEWS: In the U.S., jobless claims dropped by 5,000 to 249,000 in the week ended October 1, versus consensus expectations for 256,000 first-time claims. Gas inventories showed an 80 billion cubic feet build, above the consensus forecast for a 73 billion cubic feet build. In Europe, German factory orders increased 1% in August, boosted by domestic demand and new orders from the Eurozone. Additionally, reports indicated that Vitor Manuel Ribeiro Constancio, the VP of the European Central Bank, has disputed a prior report that the ECB was near a consensus on tapering its bond buying efforts. Reportedly Constancio said that QE will be ongoing until inflation is back on a path to the ECB's target. COMPANY NEWS: Shares of Twitter (TWTR) dropped 20% to $19.87 after Recode reported that three major companies would likely not purchase the microblog service operator - namely Walt Disney (DIS), Alphabet (GOOG; GOOGL) and Apple (AAPL). Salesforce (CRM) is said to continue to be interested in the company, and CNBC's David Faber says other suitors are considering bids as well. Meanwhile, Salesforce's shares advanced over 4%, gaining back part of yesterday's losses... Also lower was Wal-Mart (WMT), which slipped 3.2% to $69.36 after the company tempered its profit forecast for the next two fiscal years due to investments in its online business. Additionally, the world's largest retailer said store openings would slow... Yum! Brands (YUM) also slid 1.3% to $87.44 after the owner of KFC, Pizza Hut and Taco Bell missed Wall Street's quarterly earnings and sales expectations. The fast-food giant also reported a drop in sales in China as it prepares to spin off its business in the country. MAJOR MOVERS: Among the notable gainers was Zumiez (ZUMZ), which advanced 15.8% after the company reported its September same-store sales grew 6.3% and raised its third quarter earnings outlook. The shares of the teen apparel and accessories retailer were upgraded this morning at B. Riley and at William Blair following the announcement. Also higher was ICU Medical (ICUI), which gained almost 15% after the company and Pfizer (PFE) announced that they have entered into a definitive agreement under which the former will acquire all of Pfizer's global infusion therapy business, Hospira Infusion Systems, for $1B in cash and stock. Under the terms of the agreement, Pfizer will receive approximately $400M in newly issued shares of ICU Medical, resulting in Pfizer owning approximately 16.6% of ICU upon completion of the deal. Among the noteworthy losers was Alnylam Pharmaceuticals (ALNY), which plunged 48.5% after the company said it will discontinue development of Revusiran for the treatment of Familial Amyloid Cardiomyopathy. The stock has been downgraded by multiple Wall Street research firms following the news. Medicines Company (MDCO), which is partnered with Alnylam on the ALN-PCSsc program, also dropped over 8%. Also lower was Tutor Perini (TPC), which slid 6.5% after short-seller Carson Block disclosed yesterday at the Sohn San Francisco Investment Conference that he is placing a bet against the stock. Additionally, American Express (AXP) fell 3.8% after Nomura analyst Bill Carcache downgraded the stock to Reduce from Neutral, saying the combination of weaker than expected revenues and higher than expected expenses will weigh on the shares. INDEXES: The Dow fell 12.53, or 0.07%, to 18,268.50, the Nasdaq lost 9.17, or 0.17%, to 5,306.85, and the S&P 500 advanced 1.04, or 0.05%, to 2,160.77.

AAPL

Apple

$113.89

0.84 (0.74%)

GOOG

Alphabet

$776.86

0.39 (0.05%)

GOOGL

Alphabet Class A

$803.08

1.85 (0.23%)

TWTR

Twitter

$19.87

-5 (-20.10%)

DIS

Disney

$92.83

0.38 (0.41%)

CRM

Salesforce

$71.26

2.84 (4.15%)

WMT

Wal-Mart

$69.36

-2.31 (-3.22%)

YUM

Yum! Brands

$87.44

-1.18 (-1.33%)

ZUMZ

Zumiez

$21.15

2.88 (15.76%)

ICUI

ICU Medical

$144.68

18.72 (14.86%)

PFE

Pfizer

$33.65

-0.25 (-0.74%)

ALNY

Alnylam

$36.21

-34.09 (-48.49%)

MDCO

The Medicines Co.

$35.33

-3.18 (-8.26%)

TPC

Tutor Perini

$20.75

-1.45 (-6.53%)

AXP

American Express

$61.94

-2.42 (-3.76%)

  • 06

    Oct

  • 07

    Oct

  • 11

    Oct

  • 14

    Oct

  • 19

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 01

    Nov

  • 06

    Nov

  • 10

    Nov

  • 10

    Nov

  • 17

    Nov

  • 30

    Nov

  • 15

    Jan

  • 13

    Mar

AAPL Apple
$113.89

0.84 (0.74%)

10/06/16
SBSH
10/06/16
NO CHANGE
Target $89
SBSH
Buy
Citi says Salesforce buying Twitter 'nearly impossible' above $28/share
Citi analyst Walter Pritchard believes a Salesforce (CRM) acquisition of Twitter (TWTR) is possible financially but that such a deal would put "significant constraints" on the company for the next three-plus years. The analyst sees "very little reason" for Salesforce to own Twitter and feels the acquisition "would pose a difficult decision" for CEO Marc Benioff and the board. Salesforce closed yesterday down 6%, or $4.21, to $68.42. Recode reported last night that the company is likely the only bidder left for Twitter after Disney (DIS) and Alphabet (GOOG) opted not to pursue a deal while Apple (AAPL) is unlikely. Twitter in pre-market trading is down 14% to $21.50. In order for Salesforce to avoid a shareholder vote, it would have to borrow $7.5B to fund the transaction if Twitter were valued at $20B, or $27.50-$28 per share, Pritchard tells investors in a research note. This is a level that likely constrains the company with little additional borrowing capacity for other deals, the analyst contends. He thinks the deal is "nearly impossible to do" for Salesforce should the bidding for Twitter go above $20B or $28 per share. Pritchard has a Buy rating on Salesforce with an $89 price target.
10/06/16
ADAM
10/06/16
NO CHANGE
Target $140
ADAM
Buy
Apple iPhone 7 demand remains healthy, says Canaccord
Canaccord analyst T. Michael Walkley said channel checks show demand for iPhone 7 remains healthy with an ongoing strong mix leading to higher selling prices. The analyst believes the iPhone 6 and iPhone 6s products enabled Apple to materially increase its market share and installed base of the premium tier smartphone market. Walkley reiterate his Buy rating and $140 price target on Apple shares.
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Apple has positive read through from Dialog results, says RBC Capital
After Dialog issued a positive preannouncement due to higher than expected Mobile Services revenue, RBC Capital analyst Amit Daryanani thinks that the Dialog results should comfort Apple investors heading into that company's September quarter results. The analyst notes that Apple accounts for 75%-80% of Dialog's revenue. He keeps a $125 price target and Outperform rating on Apple.
10/05/16
UBSW
10/05/16
NO CHANGE
Target $127
UBSW
Buy
Apple preparing for next era of personal technology, says UBS
UBS analyst Steve Milunovich notes his residual income model for Apple shows only small growth beyond three years. He believes the current share price reflects the slight annual declines but he thinks the cautious view would be incorrect because Apple is preparing for the next era of personal technology. Milunovich calls the next phase the Ambient Paradigm, which will require hardware, software, and orchestration to provide a seamless experience across all consumer devices. The Apple Watch, AirPods, and possibly other wearables will eventually impact industries such as healthcare and education and could be the next scarcity, said Milunovich, who reiterated his Buy rating and $127 price target on Apple shares.
GOOG Alphabet
$776.86

0.39 (0.05%)

09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
Wedbush analyst James Dix downgraded Alphabet to Underperform and lowered his price target on shares to $700 on concerns the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive.
GOOGL Alphabet Class A
$803.08

1.85 (0.23%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
TWTR Twitter
$19.87

-5 (-20.10%)

10/06/16
BARD
10/06/16
NO CHANGE
Target $90
BARD
Outperform
Salesforce shares should be bought, says Baird
Baird analyst Steven Ashley noted that Salesforce (CRM) CEO Mark Benioff said his company has all the customer data it needs, which he reads as meaning it would not need to make an acquisition of Twitter (TWTR) purely for data. The analyst also said the company's board is acutely aware of their responsibility to shareholders when it comes to Salesforce's stock and the potential negative impact on shares that a Twitter deal could pose. Ashley reiterated his Outperform rating and $90 price target on Salesforce shares.
10/06/16
ROTH
10/06/16
NO CHANGE
Target $103
ROTH
Buy
Salesforce should be bought on pullback, says Roth Capital
Roth Capital analyst Richard Baldry says Salesforce's (CRM) shares are down roughly 20% from their recent highs, pressured by rumors of a potential bid for Twitter (TWTR) and a recent revenue guidance increase for the second half of 2017 that was back-end loaded enough to leave his Q3 forecast lowered. However, the analyst believes the pullback offers investors an attractive entry point and advocates buying on weakness. Baldry reiterates a Buy rating and $103 price target on Salesforce's shares given the company's strong fundamentals and sector dominance.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Salesforce shares should rebound with no Twitter deal, says Cowen
Cowen analyst J.Derrick Wood expects shares of Salesforce (CRM) to rebound if the company does not buy Twitter (TWTR), which he believes will not happen. The analyst believes investors will return to fundamentals and the analyst believes upside momentum in Salesforce's core business will return in Q3. Wood reiterated his Outperform rating and $100 price target on Salesforce shares.
DIS Disney
$92.83

0.38 (0.41%)

09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
09/26/16
09/26/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Drexel Hamilton with analyst Tony Wible saying he believes a large step up in NBA costs, incremental subscribers losses, difficult studio comps, a riskier studio slate, and Shanghai cost pressures will weigh on fiscal 2017. 2. Twitter (TWTR) downgraded to Underperform from Perform at Oppenheimer with analyst Jason Helfstein saying a media company is the most likely acquirer of Twitter and would not pay meaningfully more than the valuation implied by our price target. 3. RetailMeNot (SALE) downgraded to Sell from Hold at Stifel with analyst Scott Devitt saying third party data indicates that the company's traffic trends have deteriorated recently. 4. Finish Line (FINL) downgraded to Neutral from Buy at Buckingham with the firm's analyst believing shares will be range bound in medium term due to high comp expectations, cost savings will be offset by incentive compensation and other investments, and less compelling valuation. 5. NetApp (NTAP) downgraded to Sell from Hold at Deutsche Bank with analyst Sherri Scribner saying secular challenges in the storage market are not reflected in NetApp's current valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $16
SBSH
Neutral
Citi sees 40% downside in Twitter with no takeover bid
Citi analyst Mark May believes Twitter's (TWTR) risk/reward skews to the downside following the recent rally in the shares. A buyout of the company carries "strategic rationale for certain companies," but Twitter's "struggles and steep valuation" make a deal at a meaningful premium less likely, May tells investors in a research note. A takeover at $26 per share looks aggressive, May contends. He believes the stock could retest the lows of late May, representing 40% downside from current levels, should an acquisition offer not materialize. The analyst keeps a Neutral rating on Twitter with a $16 price target. The shares closed yesterday up 75c to $23.37 following reports that Disney (DIS) may be joining the list of potential acquires that already includes Alphabet (GOOG) and Salesforce (CRM).
CRM Salesforce
$71.26

2.84 (4.15%)

WMT Wal-Mart
$69.36

-2.31 (-3.22%)

09/30/16
GUGG
09/30/16
INITIATION
Target $82
GUGG
Buy
Wal-Mart initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated Wal-Mart with a Buy and a $82 price target saying it is successfully adapting to the rapidly changing consumer environment and remains laser focused on improving its critical U.S. supercenter business.
09/30/16
09/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Guggenheim. 2. Wal-Mart (WMT) initiated with an Overweight at KeyBanc and a Buy at Guggenheim. 3. Harley-Davidson (HOG) initiated with a Hold at Jefferies. 4. Coach (COH) was initiated with a Buy at Guggenheim while the firm initiated Michael Kors (KORS) with a Neutral. 5. First Solar (FSLR) initiated with a Buy at Williams Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
KEYB
09/29/16
INITIATION
Target $90
KEYB
Overweight
Wal-Mart initiated with an Overweight, momentum building, says KeyBanc
As previously reported, KeyBanc initiated Wal-Mart with an Overweight and a $90 price target. Analyst Edward Yruma believes Wal-Mart's investments in e-commerce and technology will drive sustainable market share gains and return the company to both consistent revenue and EBITDA growth in 2017.
09/29/16
KEYB
09/29/16
INITIATION
Target $90
KEYB
Overweight
Wal-Mart initiated with an Overweight at KeyBanc
KeyBanc initiated Wal-Mart with an Overweight and a a $90 price target.
YUM Yum! Brands
$87.44

-1.18 (-1.33%)

09/23/16
09/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from Sector Perform by RBC analyst Mark Mahaney, who cut his price target to $14 from $17. The research firm's survey of more than 1,100 advertising professionals and their attitudes towards Facebook (FB), Google (GOOG), Twitter and other high-profile names showed that, despite marketing budgets continuing to shift online, interest in the microblog platform appears to be declining. Of note, Twitter shares have surged this morning after CNBC's David Faber reported that Twitter is moving closer to selling itself and has received expressions of interest in a possible sale, although no deal is imminent. 2. Yum! Brands (YUM) downgraded to Outperform from Top Pick by RBC Capital analyst David Palmer based on valuation. His price target on Yum shares remains $97. 3. Becton Dickinson (BDX) downgraded to Sell from Neutral by Citi analyst Amit Hazan, who thinks a cyclical U.S. slowdown will push the company's organic growth below expectations. The analyst, who also sees a diminishing impact on Becton's growth from emerging markets, cut his price target for the shares to $165 from $167. 4. NextEra Energy (NEE) downgraded to Hold from Buy by Deutsche Bank analyst Jonathan Arnold, as he sees limited near-term upside with the shares up 23% year-to-date. "Extraordinarily frosty commentary" from two of three PUCT commissioners yesterday regarding NextEra's Oncor deal indicates an uphill battle in getting it approved, Arnold tells investors. 5. AVANGRID (AGR) downgraded to Underweight from Neutral by JPMorgan analyst Christopher Turnure, who thinks both the company's growth guidance and consensus expectations "appear ambitious." He lowered his price target for the shares to $41 and $44 and notes he does not have confidence in AVANGRID's near-term growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
OPCO
10/06/16
NO CHANGE
Target $97
OPCO
Outperform
Oppenheimer would be aggressive buyer of Yum! Brands below $90
After Yum! Brands reported an in-line earnings quarter, Oppenheimer analyst Brian Bittner remains attracted to the shares ahead of several catalysts. The analyst would be an aggressive buyer of Yum! Brands below $90 per share. He reiterates an Outperform rating and $97 price target on the stock.
09/29/16
BERN
09/29/16
NO CHANGE
BERN
New Yum! poised to benefit from cost cutting, unit growth, says Bernstein
Bernstein analyst Sara Senatore says that New Yum! - the global franchisor of KFC, Pizza Hut, and Taco Bell which will trade separately from the current company's China assets following an upcoming spin off - should benefit from cost cutting and steady unit growth. New Yum! will be able to cut up to $140M+.of costs, and "steady unit growth" should "provide underlying support" for its revenue, she stated. The analyst keeps a $98 price target and Outperform rating on current, combined Yum!.
09/29/16
OPCO
09/29/16
NO CHANGE
Target $97
OPCO
Outperform
Yum! Brands remains a favorite at Oppenheimer
Oppenheimer analyst Brian Bittner says Yum! Brands remains one of his "favorite Outperforms," despite its 23% year-to-date gain. The analyst raised his price target on the stock to $97 from $96, citing his updated sum-of-parts heading into the October 31 separation of the company's China business. Nonetheless, Bittner notes that this does not incorporate additional potential upside from an attractive G&A opportunity, potential for larger than expected capital returns post-separation at both entities, and continued earnings power restoration at Yum China. He reiterates an Outperform rating on the shares.
ZUMZ Zumiez
$21.15

2.88 (15.76%)

10/06/16
WBLR
10/06/16
UPGRADE
WBLR
Outperform
Zumiez upgraded to Outperform from Market Perform at William Blair
William Blair analyst Sharon Zackfia upgraded Zumiez to Outperform saying September marked the company's best comp gain since February 2015. B. Riley this morning also upgraded Zumiez.
03/11/16
BMUR
03/11/16
NO CHANGE
Target $24
BMUR
Buy
Zumiez still best-in-class, says Brean Capital
Brean Capital noted Zumiez beat the firm's estimate for Q4 earnings but gave lower than expected guidance for Q1. The firm maintained its Buy rating on Zumiez, and as it considers it "best-in-class," citing its omni-channel investments that will start impacting the top line, easing comps and signs of a pickup in business. Brean Capital maintained its $24 price target on Zumiez shares.
05/23/16
KEYB
05/23/16
NO CHANGE
KEYB
Some retailers better positioned than others to adopt to trends, says KeyBanc
After attending the Shoptalk conference, KeyBanc says that some retailers are better positioned than others to adopt to changing trends in the sector. Better positioned retailers include those "with compelling experiences," including Nordstrom (JWN), and those "with strong consumers connections," such as Lululemon (LULU), VF Corp (VFC), Oxford Industries (OXM), and Under Armour (UA), according to the firm. Conversely, retailers with large store footprints, particularly those with a significant presence in malls, "will continue to see pressure," KeyBanc believes. Among the companies in the latter category are L Brands (LB), Zumiez (ZUMZ), The Buckle (BKE), and Francesca's (FRAN), according to the firm.
10/06/16
RILY
10/06/16
UPGRADE
Target $25
RILY
Buy
Zumiez upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Zumiez to Buy after the company reported better than expected September comps and upped its Q3 outlook. The analyst raised his price target for the shares to $25 from $18.
ICUI ICU Medical
$144.68

18.72 (14.86%)

01/14/16
PIPR
01/14/16
NO CHANGE
Target $129
PIPR
Overweight
Piper views potential Pfizer divestment as neutral for ICU Medical
Piper Jaffray analyst Thomas Gunderson views Bloomberg's report that Pfizer (PFE) may be considering a sale of the infusion pump division of the recently acquired Hospira as neutral for ICU Medical (ICUI). Hospira has traditionally been ICU's largest customer, which has some worrying that if the infusion pumps are sold once again, the business could be at risk, Gunderson tells investors in a research note. He believes, however, that a Pfizer divestment could bring some upside to ICU since the infusion pump business is not in the pharma giant's "wheelhouse." Gunderson keeps an Overweight rating on ICU Medical with a $129 price target.
03/11/16
GABE
03/11/16
INITIATION
GABE
Buy
ICU Medical initiated with a Buy at Gabelli
08/09/16
ROTH
08/09/16
NO CHANGE
Target $132
ROTH
Buy
ICU Medical Direct sales momentum continues, says Roth Capital
Roth Capital analyst Chris Lewis says ICU Medical delivered a Q2 beat and raised its 2016 outlook as Direct sales momentum and OEM/Hospira growth continued. Although the company expects an even steeper decline in Hospira over the second half of 2016, the analyst believes ICU Medical is well-positioned to sustain revenue growth on Direct strength and non-Hospira OEM channels, with margin expansion opportunities materializing in 2017. Lewis reiterates a Buy rating on the stock and raised his price target on the shares to $132 from $130.
PFE Pfizer
$33.65

-0.25 (-0.74%)

09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
ALNY Alnylam
$36.21

-34.09 (-48.49%)

10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Ionis has no read through from negative Alnylam data, says Wells Fargo
After Ionis (IONS) competitor Alnylam Pharmaceuticals (ALNY) announced that it was terminating the development of its revusiran RNAi drug due to poor outcomes in clinical trials, Wells Fargo thinks that the news is "a significant positive" for Ionis because it eliminates a competitor. The firm says that Ionis' drug is significantly different than Alnylam's product, and it believes that Ionis' treatment appears to be superior. The firm keeps an Outperform rating on Ionis.
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Alnylam price target lowered to $100 from $150 at Cowen
Cowen analyst Ritu Baral noted Alnylam announced the discontinuation of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy due to risk/benefit and safety signals. The analyst does not believe it signals any risk to the platform, as other programs have shown solid safety. Baral said revusiran was a minor driver so she maintained her Outperform rating and lowered her price target to $100 from $150 on Alnylam shares.
MDCO The Medicines Co.
$35.33

-3.18 (-8.26%)

10/06/16
GUGG
10/06/16
NO CHANGE
GUGG
The Medicines Co. weakness a buying opportunity, says Guggenheim
10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
TPC Tutor Perini
$20.75

-1.45 (-6.53%)

08/24/16
08/24/16
UPGRADE
Target $28

Buy
Tutor Perini upgraded to Buy on debt repayments at MKM Partners
As previously reported, MKM Partners upgraded Tutor Perini to Buy and increased its price target to $28 from $23. Analyst Daniel Scott believes Tutor's plans to reduce uncollected billings are on track and will allow the company to reduce debt meaningfully over the next 18 months, just as earnings momentum from the FAST Act and the $42B project pipeline kicks in.
10/03/16
STPT
10/03/16
UPGRADE
STPT
Buy
Tutor Perini upgraded to Buy from Hold at Standpoint Research
08/24/16
MKMP
08/24/16
UPGRADE
MKMP
Buy
Tutor Perini upgraded to Buy from Neutral at MKM Partners
07/14/16
ADAM
07/14/16
NO CHANGE
Target $30
ADAM
Buy
Tutor Perini price target raised to $30 from $18 at Canaccord
Canaccord raised its price target on Tutor Perini to $30 from $18 to reflect the potential for upside to estimates from strength in higher margin civil revenues based on strong award activity and a robust bid pipeline. Canaccord reiterated its Buy rating on Tutor Perini shares.
AXP American Express
$61.94

-2.42 (-3.76%)

09/09/16
09/09/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Express (AXP) initiated with an Underweight at Atlantic Equities. 2. Alcoa (AA) initiated with a Neutral at Seaport Global. 3. Blue Buffalo Pet Products (BUFF) initiated with an Outperform at Oppenheimer. 4. Harley-Davidson (HOG) initiated with an Outperform at Bernstein. 5. Verifone (PAY) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
NOMU
10/06/16
DOWNGRADE
Target $56
NOMU
Reduce
American Express downgraded to Reduce from Neutral at Nomura
Nomura analyst Bill Carcache downgraded American Express (AXP) to Reduce saying the combination of weaker than expected revenues and higher than expected expenses will weigh on the shares. The third quarter is the first quarter that American Express will report excluding Costco (COST), Carcache tells investors in a research note. He expects the "tug of war between bulls and bears to intensify" in Q3 and thinks 2016 will mark the fourth year of market share losses in U.S. billings. The analyst cut his price target for the shares to $56 from $62.
10/06/16
10/06/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Neutral from Buy at Goldman with analyst David Tamberrino saying he sees incremental risk to Tesla's business related to management's willingness to deploy capital for M&A, and he believes that any delay in the company's new Model 3 launch will be detrimental to shares. 2. JPMorgan (JPM) downgraded to Hold from Buy at Sandler O'Neill with analyst Jeffery Harte citing relative share outperformance. 3. Abercrombie & Fitch (ANF) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jessica Schmidt saying the elevated promotions add to other headwinds, including the fact that the teen space is "overstored" and faces soft consumer demand and weak tourism. 4. American Express (AXP) downgraded to Reduce from Neutral at Nomura with analyst Bill Carcache saying the combination of weaker than expected revenues and higher than expected expenses will weigh on the shares. 5. Lowe's (LOW) downgraded to Neutral from Buy at Cleveland Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
ATLE
09/09/16
INITIATION
Target $62
ATLE
Underweight
American Express initiated with an Underweight at Atlantic Equities
Atlantic Equities initiated American Express with an Underweight and $62 price target.

TODAY'S FREE FLY STORIES

PES

Pioneer Energy

$6.70

0.45 (7.20%)

05:31
12/07/16
12/07
05:31
12/07/16
05:31
Syndicate
Pioneer Energy 10.5M share Spot Secondary priced at $5.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SLM

Sallie Mae

$10.78

0.23 (2.18%)

05:30
12/07/16
12/07
05:30
12/07/16
05:30
Initiation
Sallie Mae initiated  »

Sallie Mae initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIK

Michaels

$23.85

-0.46 (-1.89%)

05:29
12/07/16
12/07
05:29
12/07/16
05:29
Downgrade
Michaels rating change  »

Michaels downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$71.97

0.3 (0.42%)

05:28
12/07/16
12/07
05:28
12/07/16
05:28
Downgrade
Kellogg rating change  »

Kellogg downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$17.03

0.03 (0.18%)

05:28
12/07/16
12/07
05:28
12/07/16
05:28
Initiation
Navient initiated  »

Navient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRSK

Verisk Analytics

$83.04

0.13 (0.16%)

05:25
12/07/16
12/07
05:25
12/07/16
05:25
Initiation
Verisk Analytics initiated  »

Verisk Analytics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

CMCO

Columbus McKinnon

$27.59

1.07 (4.03%)

05:25
12/07/16
12/07
05:25
12/07/16
05:25
Hot Stocks
Columbus McKinnon to acquire STAHL CraneSystems for about $240M »

Columbus McKinnon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLGX

CoreLogic

$37.89

-0.28 (-0.73%)

05:24
12/07/16
12/07
05:24
12/07/16
05:24
Initiation
CoreLogic initiated  »

CoreLogic initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

MGP

MGM Growth

$24.60

-0.18 (-0.73%)

, GLPI

Gaming and Leisure Properties

$30.70

0.24 (0.79%)

05:21
12/07/16
12/07
05:21
12/07/16
05:21
Downgrade
MGM Growth, Gaming and Leisure Properties, Boyd Gaming rating change  »

MGM Growth downgraded to…

MGP

MGM Growth

$24.60

-0.18 (-0.73%)

GLPI

Gaming and Leisure Properties

$30.70

0.24 (0.79%)

BYD

Boyd Gaming

$19.63

0.39 (2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASX

Advanced Semiconductor

$5.38

0.11 (2.09%)

05:20
12/07/16
12/07
05:20
12/07/16
05:20
Hot Stocks
Advanced Semiconductor reports Nov. revenue up 1.3% to $821M »

Reports November ATM net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$70.14

1.08 (1.56%)

05:19
12/07/16
12/07
05:19
12/07/16
05:19
Hot Stocks
Acacia Communications establishes EMEA-APAC headquarters in Limerick, Ireland »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.96

-0.01 (-0.01%)

05:18
12/07/16
12/07
05:18
12/07/16
05:18
Hot Stocks
Novartis drug Lucentis receives EU approval in new indication »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$63.85

1.76 (2.83%)

05:18
12/07/16
12/07
05:18
12/07/16
05:18
Recommendations
Western Digital analyst commentary  »

Western Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$12.56

0.12 (0.96%)

05:16
12/07/16
12/07
05:16
12/07/16
05:16
Hot Stocks
Ford reports Nov. China sales up 17% to 124,113 vehicles »

Ford and its joint…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 10

    Jan

MU

Micron

$19.06

0.45 (2.42%)

05:15
12/07/16
12/07
05:15
12/07/16
05:15
Initiation
Micron initiated  »

Micron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Dec

ESGR

Enstar Group

$194.15

0.5 (0.26%)

05:12
12/07/16
12/07
05:12
12/07/16
05:12
Hot Stocks
Enstar Group announces reinsurance of QBE Legacy U.S. business »

Enstar Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRUE

TrueCar

$12.44

0.02 (0.16%)

05:10
12/07/16
12/07
05:10
12/07/16
05:10
Recommendations
TrueCar analyst commentary  »

TrueCar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWI

Titan International

$11.68

0.08 (0.69%)

05:10
12/07/16
12/07
05:10
12/07/16
05:10
Hot Stocks
Titan International appoints interim CFO James Froisland to CFO »

The board of Titan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANET

Arista Networks

$93.86

1.11 (1.20%)

, HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

05:08
12/07/16
12/07
05:08
12/07/16
05:08
Recommendations
Arista Networks, HP Enterprise analyst commentary  »

Arista Networks price…

ANET

Arista Networks

$93.86

1.11 (1.20%)

HPE

HP Enterprise

$23.96

-0.25 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

DPSGY

Deutsche Post

$31.62

0.015 (0.05%)

05:03
12/07/16
12/07
05:03
12/07/16
05:03
Upgrade
Deutsche Post rating change  »

Deutsche Post upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLLLY

Delta Lloyd

05:03
12/07/16
12/07
05:03
12/07/16
05:03
Upgrade
Delta Lloyd rating change  »

Delta Lloyd upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSREY

Swiss Re

$23.68

0.195 (0.83%)

05:02
12/07/16
12/07
05:02
12/07/16
05:02
Upgrade
Swiss Re rating change  »

Swiss Re upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZURVY

Zurich Insurance

$26.82

0.365 (1.38%)

05:01
12/07/16
12/07
05:01
12/07/16
05:01
Upgrade
Zurich Insurance rating change  »

Zurich Insurance upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AV

Aviva

$11.86

0.36 (3.13%)

05:00
12/07/16
12/07
05:00
12/07/16
05:00
Upgrade
Aviva rating change  »

Aviva upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Billiton

$38.34

-0.4 (-1.03%)

04:58
12/07/16
12/07
04:58
12/07/16
04:58
Downgrade
BHP Billiton rating change  »

BHP Billiton downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.